Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Final 72-Week Analyses of Phase 3 HOPE Study Demonstrat e Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status
GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States
07:00am, Wednesday, 02'nd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe an
GBT Announces Participation in Upcoming Investor Conferences
08:00am, Wednesday, 25'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtu
Global Blood Therapeutics: 40% Discount On A Billion-Dollar Drug
06:20pm, Thursday, 19'th Nov 2020
GBT has the only approved drug that can completely reverse sickle cell disease, which is affecting over 250k people worldwide. It has been subjected to an unwarranted selloff due to a slower than expe
Global Blood Therapeutics News: 5 Things for GBT Stock Investors to Know as Shares Tumble
12:24pm, Friday, 06'th Nov 2020
Global Blood Therapeutics (GBT) news for Friday includes poor results from its third-quarter earnings report sending GBT stock lower. The post Global Blood Therapeutics News: 5 Things for GBT Stock In
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2020 Results - Earnings Call Transcript
07:49pm, Thursday, 05'th Nov 2020
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2020 Results - Earnings Call Transcript
GBT Reports Recent Business Progress and Third Quarter 2020 Financial Results
04:05pm, Thursday, 05'th Nov 2020
Achieved Oxbryta ® (voxelotor) net revenues of $ 36. 9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months of 2020
GBT Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition
03:11pm, Wednesday, 04'th Nov 2020
Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting Long-Term Use of Oxbryta ® ( voxelotor )
GBT to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020
08:00am, Thursday, 29'th Oct 2020
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on Thursday
Global Blood Therapeutics (GBT) Investor Presentation - Slideshow
05:39pm, Friday, 11'th Sep 2020Mutual of America Capital Management LLC Sells 3,176 Shares of Global Blood Therapeutics Inc (NASDAQ:GBT)
08:10am, Saturday, 22'nd Aug 2020
Mutual of America Capital Management LLC decreased its position in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 6.3% in the 2nd quarter, according to its most recent Form 13F filing with th
Global Blood Therapeutics: Investment Risk Diminishing As Oxbryta Outperforms
11:44am, Thursday, 20'th Aug 2020
Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the pandemic era.
Janney Montgomery Scott LLC Sells 1,948 Shares of Global Blood Therapeutics Inc (NASDAQ:GBT)
10:58am, Tuesday, 11'th Aug 2020
Janney Montgomery Scott LLC lessened its holdings in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 25.6% during the 2nd quarter, according to the company in its most recent disclosure with t
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
12:00am, Tuesday, 11'th Aug 2020
The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
GBT Announces New Employment Inducement Grants
12:00pm, Friday, 07'th Aug 2020
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2020, the compensation committee of GBT’s board o
